Physicians and researchers at Cincinnati Children’s participate in numerous clinical research projects in hopes of improving the prognosis and quality of life for patients with brain tumors.

Some studies are sponsored by physicians and researchers at Cincinnati Children’s. Many others are offered at our site through national institutions such as the National Cancer Institute, Children’s Oncology Group and the Collaborative Ependymoma Research Network. Participation in these consortiums provides patients with early access to new anti-cancer therapies.

Current clinical research projects focus on:

  • Novel chemotherapy combinations for patients with relapsed or refractory (treatment-resistant) tumors 
  • Anti-angiogenic (tumor blood vessel-targeted) therapy regimens 
  • Targeted small molecule anticancer drugs 
  • High-dose therapy regimens with blood and marrow transplantation 
  • Viral therapy 
  • Quality-of-life issues following treatment

One clinical research study of note is a Cincinnati Children’s-based pilot study for patients with newly diagnosed, high-grade gliomas and diffuse intrinsic brain stem gliomas. This study incorporates standard therapy with a promising anti-angiogenic agent that is designed to prevent blood vessel growth  to stop the tumor from growing. The study also is asking several important questions regarding the biology of these tumors and the quality of life and functional outcomes of these patients.

National Referral Center

Cincinnati Children’s is a major referral center for the national Children’s Oncology Group, the National Cancer Institute’s new Pediatric Phase I Consortium and the new Department of Defense Neurofibromatosis Clinical Consortium.

Cincinnati Children’s is also a member of the Collaborative Ependymoma Research Network (CERN) and is leading some studies through the Pediatric Brain Tumor Consortium. As such, our patients have access to the latest anti-cancer drug development clinical research studies, some of them pioneered right here at Cincinnati Children’s. Many of our physicians serve in leadership roles for these research organizations, further strengthening our link to the latest advances in clinical research and care.